Product and Pipeline Analysis of the Global Colorectal Cancer Market

Product and Pipeline Analysis of the Global Colorectal Cancer Market

Targeted Therapeutics and Immunology Combine to Take Colorectal Cancer Treatments to the Next Level

RELEASE DATE
09-Sep-2015
REGION
North America
Research Code: M986-01-00-00-00
SKU: LS00095-NA-MR_16936
AvailableYesPDF Download
$3,950.00
In stock
SKU
LS00095-NA-MR_16936
$3,950.00
DownloadLink
ENQUIRE NOW

Description

Research Overview


This Frost & Sullivan research service on the global colorectal cancer market provides in-depth analyses of industry trends, market shares, competitive analysis, market opportunities and revenue forecasts from 2014 to 2021. It also features a SWOT analysis of drugs that are available in the market as well as those under development. In this market research, Frost & Sullivan's expert analysts thoroughly examine the following modalities:



  • targeted therapies

  • cytotoxics

  • cancer vaccines

  • other products (bone calcium regulators, cytotoxic antibiotics, anti-cancer agents, immunostimulants, alkylating agents and anti-metabolites).


The evaluation of each drug class is supported by information on clinical trials, projected launch timelines, and epidemiology.


Market Overview


Strong drug pipeline continues to expand


The pipeline for colorectal cancer treatment boasts a vast number and variety of remedies. The high incidence of the disease, unmet treatment needs and their commercial potential attracts drug developers to the market. Advancements are centred on identifying new molecular targets and reducing toxicity. Several immunotherapies and cancer vaccines are being developed as pharmaceutical and biotech companies attempt to utilise the body's own immune system mechanism to attack tumours. Immune-based therapies will play a vital role in future cancer treatment as they can increase survival rates and overcome patients' resistance to existing therapeutics.


Colorectal cancer care edges toward personalisation


With the increasing focus on treatment outcomes, the market for colorectal cancer is undoubtedly moving toward personalised modes of care. Targeted solutions dominate the colorectal cancer pipeline, accounting for 60 percent of the treatment modalities under production. The improved understanding of the molecular mechanisms of colorectal cancer will facilitate the identification of newer targets and give rise to multi-targeted therapies. Meanwhile, biomarker testing is expected to become the standard of care, as it can help select a targeted therapy for a patient's particular need (predictive biomarkers), as well as define the patient's specific tumour type (prognostic biomarkers).


Beyond effective care delivery, employing targeted solutions will greatly enhance the reimbursement potential. By treating patients that are most likely to respond to a particular therapy, healthcare givers will be able to better justify the high costs to insurance firms and government payers. Therefore, clinical trials of targeted therapy drugs using biomarkers as surrogate endpoints will boost their chances of approval. Ultimately, the use of targeted remedies, coupled with immunotherapy, though complicated, will bridge the gap between the current need and future scope of colorectal cancer treatment globally.

Table of Contents

Executive Summary

Executive Summary (continued)

Executive Summary (continued)

Executive Summary (continued)

Executive Summary (continued)

Physician Treatment Guidelines—Lines of Therapy

Key Trends

Market Opportunities

Companies to Watch

Methodology and Scope

Market Overview—Types of Treatment in Development

Market Overview—Global Incidences of CRC

Market Overview—US Incidence Rates by Year and Sex

Market Overview—Biomarker Type Segmentation

Market Overview—Key Mergers, Acquisitions, and Partnerships

Market Overview—Recent Developments

Global CRC Market—Revenue Forecast

Revenue Forecast Discussion

Revenue Forecast Discussion (continued)

Revenue Forecast Discussion (continued)

Competitive Landscape Overview

Competitive Landscape—Phase III to Launch

Competitive Landscape—Phase II

Competitive Landscape—Phase I

Key Marketed Products

Key Marketed Products (continued)

Key Marketed Products (continued)

Key Marketed Products (continued)

Pipeline Synopsis—Phase III

Pipeline Synopsis—Phase III (continued)

Pipeline Synopsis—Phase III (continued)

Pipeline Synopsis—Phase III (continued)

Pipeline Synopsis—Phase III (continued)

Pipeline Synopsis—Phase II

Pipeline Synopsis—Phase II (continued)

Pipeline Synopsis—Phase II (continued)

Pipeline Synopsis—Phase II (continued)

Pipeline Synopsis—Phase II (continued)

Pipeline Synopsis—Phase II (continued)

Pipeline Synopsis—Phase II (continued)

Pipeline Synopsis—Phase II (continued)

Pipeline Synopsis—Phase II (continued)

Pipeline Synopsis—Phase II (continued)

Pipeline Synopsis—Phase II (continued)

Pipeline Synopsis—Phase II (continued)

Pipeline Synopsis—Phase II (continued)

Pipeline Synopsis—Phase II (continued)

Pipeline Synopsis—Phase I

Pipeline Synopsis—Phase I (continued)

Pipeline Synopsis—Phase I (continued)

Pipeline Synopsis—Phase I (continued)

Pipeline Synopsis—Phase I (continued)

Pipeline Synopsis—Phase I (continued)

Competitive Landscape—Pivotal Phase III Trials

Timeline of Key Events

Patent Expirations

Pipeline Discussion

Pipeline Discussion (continued)

Product Dashboard: Avastin (Bevacizumab)—Genentech Inc. (Roche Group)

Avastin (Genentech, Roche)—SWOT Analysis

Product Dashboard—BBI503: Boston Biomedical

BBI503 (Boston Biomedical)—SWOT Analysis

Product Dashboard—Cyramza (ramicirumab): Eli Lilly

Cyramza (ramicirumab) (Eli Lilly)—SWOT Analysis

Product Dashboard—Erbitux (cetuximab): Eli Lilly/BMS/Merck

Erbitux (Eli Lilly, BMS, and Merck)—SWOT Analysis

Product Dashboard—Imprime PGG: Biothera

Imprime PGG (Biothera)—SWOT Analysis

Product Dashboard—Lonsurf (TAS-102): Taiho (Otsuka)

Lonsurf (TAS–102) (Taiho, Otsuka)—SWOT Analysis

Product Dashboard—MGN1703: Mologen

MGN1703 (Mologen)—SWOT Analysis

Product Dashboard—Nintedanib (BIBF-1120, OFEV): Boehringer Ingelheim

Nintedanib (BIBF–1120, OFEV) (BI)—SWOT Analysis

Product Dashboard—Stivarga (regorafenib): Bayer/Onyx Pharmaceuticals

Stivarga (Bayer, Onyx)—SWOT Analysis

Product Dashboard—Zaltrap (aflibercept): Sanofi

Zaltrap (aflibercept) (Sanofi)—SWOT Analysis

Conclusions

Conclusions (continued)

The Last Word—3 Big Predictions

The Last Word—Discussion

Legal Disclaimer

The Frost & Sullivan Story

Value Proposition: Future of Your Company & Career

Global Perspective

Industry Convergence

360º Research Perspective

Implementation Excellence

Our Blue Ocean Strategy

Related Research
This deliverable provides research and analysis of the global infectious disease diagnostics market. It includes an in-depth analysis of revenue forecast by segment, drivers and restraints, and technology trends, along with the competitive factors and strategies, and key companies to watch. The global market is primarily driven by the high prevalence of these diseases and the growing demand for rapid diagnostic tests. Regional breakdowns are provided for three market segments: immunodiagnostics, molecular methods, and clinical microbiology. Regional breakdowns by disease also are provided. The base year for the study is 2013; the forecast period is from 2014 to 2018.
More Information
No Index No
Podcast No
Author Barbara Gilmore
WIP Number M986-01-00-00-00
Keyword 1 Global Colorectal Cancer
Keyword 2 Colorectal Cancer
Keyword 3 Pipeline Analysis of the Colorectal Cancer
Is Prebook No